Loading
A phase 2 trial of Pembrolizumab in melanoma, run by Philogen S.p.A., now recruiting.
Study of the Efficacy of Intratumoral L19IL2 or L19TNF or L19IL2/L19TNF, in Combination With Pembrolizumab, in Unresectable Melanoma Patients is a phase 2 interventional study registered as NCT06284590 by Philogen S.p.A., with 162 participants planned, started 2024-07-12 and due to reach its primary completion in 2028-07. Interventions recorded: L19IL2, L19TNF, L19IL2/L19TNF, KEYTRUDA®. Conditions listed: Melanoma Stage III, Melanoma Stage IV. No results are recorded here; the registry entry is the source.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma, Pembrolizumab, Immune checkpoint inhibitors.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma, Pembrolizumab, Immune checkpoint inhibitors.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma, Pembrolizumab, Immune checkpoint inhibitors.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma, Pembrolizumab, Immune checkpoint inhibitors.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma, Immune checkpoint inhibitors.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma, Pembrolizumab, Immune checkpoint inhibitors.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma, Pembrolizumab.
Shares Advanced melanoma (unresectable stage III and stage IV), Melanoma, Immune checkpoint inhibitors.